

Diane M Harper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1268226/publications.pdf>

Version: 2024-02-01

139
papers

15,443
citations

108046

37
h-index

23841

115
g-index

144
all docs

144
docs citations

144
times ranked

11661
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of INHERET, an Online Family History and Cancer Risk Interpretation Program for Primary Care and Specialty Clinics. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 63-70.	2.3	4
2	Concordant physician-patient characteristics lose importance for Arab American women and their healthcare- cross-sectional study. <i>The Lancet Regional Health Americas</i> , 2022, 10, 100225.	1.5	2
3	Comparative predictors for cervical cancer screening in Southeast Michigan for Middle Eastern-North African (MENA), White and African American/black women. <i>Preventive Medicine</i> , 2022, , 107054.	1.6	5
4	Vasectomy Training in Family Medicine Residency Programs: A National Survey of Residency Program Directors. <i>Family Medicine</i> , 2022, 54, 438-443.	0.3	0
5	Annual HIV screening rates for HIV-negative men who have sex with men in primary care. <i>PLoS ONE</i> , 2022, 17, e0266747.	1.1	2
6	The future of cancer screening after COVID-19 may be at home. <i>Cancer</i> , 2021, 127, 498-503.	2.0	51
7	Disability Policies and Practices in Family Medicine Residencies: A CERA Study. <i>Family Medicine</i> , 2021, 53, 211-214.	0.3	2
8	Predictors of Human Papillomavirus Seropositivity in Appalachian Women Aged 18 to 26 Years. <i>Sexually Transmitted Diseases</i> , 2021, 48, 693-699.	0.8	0
9	HPV Vaccination Among Young Adults in the US. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1673.	3.8	25
10	Health-Related Quality of Life for People With Acute and Chronic Illnesses During the COVID-19 Pandemic. <i>Journal of the American Board of Family Medicine</i> , 2021, 34, 509-521.	0.8	11
11	Prevalence, Plans, and Perceptions: Disability in Family Medicine Residencies. <i>Family Medicine</i> , 2021, 53, 338-346.	0.3	6
12	Family Medicine Residents'™ Experience During Early Phases of the COVID-19 Pandemic. <i>PRIMER (Leawood,)</i> Tj ETQqO 0 0 rgBT /Overl	0.6	3
13	Rigorous review and editorial oversight of clinical preprints. <i>ELife</i> , 2021, 10, .	2.8	2
14	Family Medicine Researchers'™ Why? Who? How? When?. <i>Family Medicine</i> , 2021, 53, 647-649.	0.3	2
15	Predictors of screening for cervical and colorectal cancer in women 50-65 years old in a multi-ethnic population. <i>Preventive Medicine Reports</i> , 2021, 22, 101375.	0.8	10
16	Cancer risk perception and physician communication behaviors on cervical cancer and colorectal cancer screening. <i>ELife</i> , 2021, 10, .	2.8	12
17	Annual Wellness Visits for Persons With Physical Disabilities Before and After ACA Implementation. <i>Annals of Family Medicine</i> , 2021, 19, 484-491.	0.9	0
18	Elimination of cervical cancer depends on HPV vaccination and primary HPV screening. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1342-1344.	4.6	4

#	ARTICLE	IF	CITATIONS
19	Streamlining the WHO cervical cancer elimination goal. <i>Lancet Oncology</i> , The, 2021, 22, 1484-1485.	5.1	1
20	Patient-Centered Home Cancer Screening Attitudes During COVID-19 Pandemic. <i>Journal of Patient-centered Research and Reviews</i> , 2021, 8, 340-346.	0.6	7
21	Transgender Education in North American Family Medicine Clerkships: A CERA Study. <i>Family Medicine</i> , 2021, 53, 676-683.	0.3	1
22	Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45-65 years of age in the United States. <i>Preventive Medicine</i> , 2020, 130, 105880.	1.6	27
23	The vaginal microbiota, high-risk human papillomavirus infection, and cervical cytology: results from a population-based study. <i>Gynecology and Pelvic Medicine</i> , 2020, 3, 18-18.	0.1	4
24	HPV vaccination bridges to HPV screening. <i>EClinicalMedicine</i> , 2020, 23, 100435.	3.2	0
25	Awareness and Attitudes Around the New Subspecialty Within Ob/Gyn Called Complex Family Planning: A CERA Survey of Family Medicine Chairs. <i>Family Medicine</i> , 2020, 52, 702-706.	0.3	1
26	Implementing a "publish, then review" model of publishing. <i>ELife</i> , 2020, 9, .	2.8	25
27	The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. <i>Gynecologic Oncology</i> , 2019, 153, 521-529.	0.6	43
28	Postpartum endometritis and infection following incomplete or complete abortion: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. <i>Vaccine</i> , 2019, 37, 7585-7595.	1.7	22
29	Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. <i>Sexually Transmitted Diseases</i> , 2019, 46, 663-669.	0.8	10
30	Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 114-121.	4.5	29
31	Examining Feasibility and Support in Prescribing a Plant-based Diet to Patients with Chronic Diseases in a Primary Care Practice. <i>Alternative & Integrative Medicine</i> , 2018, 07, .	0.1	0
32	Optimizing Women's Health in Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2018, 45, xiii-xiv.	0.7	0
33	Will increasing dosing intervals decrease the loss of anti-HPV seropositivity over time?. <i>Vaccine</i> , 2018, 36, 4966.	1.7	1
34	Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. <i>Journal of Infectious Diseases</i> , 2018, 218, 84-94.	1.9	16
35	HPV vaccines - A review of the first decade. <i>Gynecologic Oncology</i> , 2017, 146, 196-204.	0.6	304
36	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	3.0	43

#	ARTICLE	IF	CITATIONS
37	Hypothesis generating data â€“ HPV vaccines â€“ A decade in review. <i>Gynecologic Oncology Reports</i> , 2017, 22, 115-116.	0.3	0
38	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. <i>BMJ Open</i> , 2016, 6, e011371.	0.8	34
39	Screening for Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1372.	3.8	166
40	Associations between prior HPV4 vaccine doses and cervical cancer screening participation. <i>Cancer Epidemiology</i> , 2016, 42, 108-114.	0.8	13
41	Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. <i>Expert Review of Vaccines</i> , 2016, 15, 367-387.	2.0	46
42	Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2016, 34, 6093-6101.	1.7	13
43	Screening for Syphilis Infection in Nonpregnant Adults and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2321.	3.8	104
44	Screening for Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2564.	3.8	1,725
45	Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. <i>International Journal of Cancer</i> , 2016, 138, 2428-2438.	2.3	80
46	No evidence in US of HPV16/18 cancer precursor reduction. <i>Vaccine</i> , 2016, 34, 200.	1.7	1
47	Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population. <i>Preventive Medicine Reports</i> , 2015, 2, 711-716.	0.8	21
48	<i>Post Hoc</i> Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA. <i>Vaccine Journal</i> , 2015, 22, 235-244.	3.2	16
49	IV3 reduced flu in HIV+ pregnant women and infants, and in HIV+ pregnant women but not their infants. <i>Annals of Internal Medicine</i> , 2015, 162, JC6.	2.0	0
50	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	5.1	247
51	Response to philanthropic support of HPV vaccination efforts. <i>Preventive Medicine</i> , 2015, 76, 127-128.	1.6	0
52	Incorporating Osteopathic Curriculum Into a Family Medicine Residency. <i>Family Medicine</i> , 2015, 47, 794-8.	0.3	2
53	Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. <i>PLoS ONE</i> , 2014, 9, e88493.	1.1	9
54	Women Have a Preference for Their Male Partner to Be HPV Vaccinated. <i>PLoS ONE</i> , 2014, 9, e97119.	1.1	8

#	ARTICLE	IF	CITATIONS
55	In a Safety Net Population HPV4 Vaccine Adherence Worsens as BMI Increases. PLoS ONE, 2014, 9, e103172.	1.1	5
56	Positive High-Risk HPV Test with Negative Cytology—A Conundrum and Blessing of Our Latest Technology. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 10-11.	1.1	0
57	Conclusions About the Quadrivalent Human Papillomavirus Vaccine Efficacy Based on Alternate Dosing Schedules and Less Than Three Dose Immunogenicity is Inappropriate. Journal of Infectious Diseases, 2014, 210, 330-331.	1.9	1
58	Primary Strategies for HPV Infection and Cervical Cancer Prevention. Clinical Obstetrics and Gynecology, 2014, 57, 256-278.	0.6	30
59	Reduction in HPV Prevalence—No Evidence to Support HPV Vaccination reduces HPV Prevalence. Journal of Infectious Diseases, 2014, 209, 1302-1304.	1.9	1
60	The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Preventive Medicine, 2014, 61, 20-25.	1.6	15
61	Urban and Rural Safety Net Health Care System Clinics: No Disparity in HPV4 Vaccine Completion Rates. PLoS ONE, 2014, 9, e96277.	1.1	2
62	Cross protection against HPV might prevent type replacement. Lancet Infectious Diseases, The, 2013, 13, 195.	4.6	8
63	Speculation overinflates long-term efficacy of vaccine for anal dysplasia. Lancet Oncology, The, 2013, 14, e249-e250.	5.1	0
64	Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized) Tj ETQq0 0.0 rgBT /Overlock 10	1.9	73
65	RE: Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels and RE: Inequalities in Human Papillomavirus (HPV)-Associated Cancers: Implications for the Success of HPV Vaccination. Journal of the National Cancer Institute, 2013, 105, 749-750.	3.0	11
66	Review: Combined oral contraceptives are associated with venous thrombosis. Annals of Internal Medicine, 2013, 159, JC12.	2.0	1
67	Review: Yoga reduces low back pain and back-specific disability. Annals of Internal Medicine, 2013, 159, JC13.	2.0	0
68	Quantifying Clinical HPV4 Dose Inefficiencies in a Safety Net Population. PLoS ONE, 2013, 8, e77961.	1.1	6
69	Predictors of Three Dose On-Time Compliance with HPV4 Vaccination in a Disadvantaged, Underserved, Safety Net Population in the US Midwest. PLoS ONE, 2013, 8, e71295.	1.1	16
70	Long-Term Follow-Up of HPV16-Positive Women: Persistence of the Same Genetic Variant and Low Prevalence of Variant Co-Infections. PLoS ONE, 2013, 8, e80382.	1.1	11
71	Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 100-110.	5.1	432
72	Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecologic Oncology, 2012, 127, 440-450.	0.6	55

#	ARTICLE	IF	CITATIONS
73	Prophylactic HPV Vaccines and Prevention of Cervical Intraepithelial Neoplasia. Current Obstetrics and Gynecology Reports, 2012, 1, 95-105.	0.3	8
74	Prevention of HPV-Associated Diseases in the United States. , 2012, , 211-255.		0
75	3q26 Amplification Is an Effective Negative Triage Test for LSIL: A Historical Prospective Study. PLoS ONE, 2012, 7, e39101.	1.1	10
76	Efficacy of the human papillomavirus (HPV)â€16/18 AS04â€adjuvanted vaccine in women aged 15â€25 years with and without serological evidence of previous exposure to HPVâ€16/18. International Journal of Cancer, 2012, 131, 106-116.	2.3	109
77	Who should be targeted for vaccination against anal cancer?. Lancet Oncology, The, 2011, 12, 828-829.	5.1	6
78	Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstetrics & Gynecology, 2011, 2011, 1-20.	1.2	27
79	HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine, 2011, 364, 2163-2165.	13.9	5
80	Review of Gardasil. Journal of Vaccines & Vaccination, 2010, 01, .	0.3	22
81	Cervical cancer incidence can increase despite HPV vaccination. Lancet Infectious Diseases, The, 2010, 10, 594-595.	4.6	38
82	Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discovery Medicine, 2010, 10, 7-17.	0.5	49
83	Smoking Enhances Risk for New External Genital Warts in Men. International Journal of Environmental Research and Public Health, 2009, 6, 1215-1234.	1.2	19
84	Clinical diagnosis of vaginitis was moderately accurate in symptomatic women. Evidence-Based Medicine, 2009, 14, 88-88.	0.6	1
85	Currently approved prophylactic HPV vaccines. Expert Review of Vaccines, 2009, 8, 1663-1679.	2.0	133
86	Prevention of Human Papillomavirus Infections and Associated Diseases by Vaccination: A New Hope for Global Public Health. Public Health Genomics, 2009, 12, 319-330.	0.6	31
87	GardasilÂ®needs a new consent form. Expert Review of Vaccines, 2009, 8, 1613-1614.	2.0	2
88	Preliminary HPV vaccine results for women older than 25 years. Lancet, The, 2009, 373, 1921-1922.	6.3	22
89	Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6Â4 years. Lancet, The, 2009, 374, 1975-1985.	6.3	328
90	Cervico-Isthmic Corporeal Pregnancy With Delivery at Term: A Review of the Literature With a Case Report. Obstetrical and Gynecological Survey, 2009, 64, 335-344.	0.2	24

#	ARTICLE	IF	CITATIONS
91	Current prophylactic HPV vaccines and gynecologic premalignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 457-464.	0.9	24
92	Impact of vaccination with Cervarix, on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. <i>Gynecologic Oncology</i> , 2008, 110, S11-S17.	0.6	62
93	Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix]. <i>Drugs</i> , 2008, 68, 359-372.	4.9	81
94	Age for HPV vaccination. <i>Vaccine</i> , 2008, 26, A7-A11.	1.7	26
95	Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix]. <i>BioDrugs</i> , 2008, 22, 205-208.	2.2	11
96	Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 313-324.	0.2	15
97	Human papillomavirus and HPV vaccines: a review. <i>Bulletin of the World Health Organization</i> , 2007, 85, 719-726.	1.5	297
98	Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines. <i>Vaccine Journal</i> , 2007, 14, 792-795.	3.2	35
99	The Effect of Oral Contraceptives on Bone Mass and Stress Fractures in Female Runners. <i>Medicine and Science in Sports and Exercise</i> , 2007, 39, 1464-1473.	0.2	117
100	Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. <i>Lancet, The</i> , 2007, 369, 1693-1702.	6.3	579
101	Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. <i>Lancet, The</i> , 2007, 369, 2161-2170.	6.3	1,153
102	Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. <i>New England Journal of Medicine</i> , 2007, 356, 1928-1943.	13.9	1,741
103	American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 7-28.	157.7	443
104	Quadrivalent HPV vaccine prevented cervical neoplasia caused by HPV-16 and HPV-18. <i>ACP Journal Club</i> , 2007, 147, 49.	0.1	1
105	Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. <i>Lancet, The</i> , 2006, 367, 1247-1255.	6.3	1,395
106	Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. <i>Vaccine</i> , 2006, 24, 5571-5583.	1.7	380
107	Chapter 13: Current findings from prophylactic HPV vaccine trials. <i>Vaccine</i> , 2006, 24, S114-S121.	1.7	120
108	Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial. <i>Obstetrical and Gynecological Survey</i> , 2005, 60, 171-173.	0.2	43

#	ARTICLE	IF	CITATIONS
109	How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts. <i>International Journal of STD and AIDS</i> , 2005, 16, 203-211.	0.5	11
110	Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. <i>Lancet Oncology</i> , The, 2005, 6, 271-278.	5.1	1,400
111	Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. <i>Vaccine</i> , 2005, 23, 2388-2394.	1.7	187
112	Are we closer to the prevention of HPV-related diseases?. <i>Journal of Family Practice</i> , 2005, Suppl HPV Prevention, S10-6; quiz S23.	0.2	0
113	Magnification and Chromoscopy with the Acetic Acid Test. <i>Endoscopy</i> , 2004, 36, 748-750.	1.0	5
114	Beyond the Pap: Assessing Patients' Priorities for the Annual Examination. <i>Journal of Women's Health</i> , 2004, 13, 791-799.	1.5	11
115	Why Am I Scared of HPV?. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 245-247.	157.7	34
116	Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1249-1257.	0.7	88
117	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. <i>Lancet</i> , The, 2004, 364, 1757-1765.	6.3	1,435
118	Factors Affecting the Detection Rate of Human Papillomavirus. <i>Annals of Family Medicine</i> , 2003, 1, 221-227.	0.9	41
119	Tampon Samplings With Longer Cervicovaginal Cell Exposures Are Equivalent to Two Consecutive Swabs for the Detection of High-Risk Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2002, 29, 628-636.	0.8	31
120	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 342-362.	157.7	782
121	Randomized clinical trial of PCR-determined human papillomavirus detection methods: Self-sampling versus clinician-directed—Biologic concordance and women's preferences. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 365-373.	0.7	104
122	Self-screening methods are the next public health improvement for sexually transmitted infection detection. <i>JAMA Pediatrics</i> , 2002, 156, 1154-5.	3.6	0
123	Healing Experiences After Cervical Cryosurgery. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 113-113.	0.9	0
124	Analysis of acetic acid-induced whitening of high-grade squamous intraepithelial lesions. <i>Journal of Biomedical Optics</i> , 2001, 6, 397.	1.4	53
125	Self-reported desire to improve colposcopic impressions. <i>Archives of Gynecology and Obstetrics</i> , 2000, 264, 137-142.	0.8	1
126	Treatment threshold probability for vaginitis. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 517-518.	0.7	1

#	ARTICLE	IF	CITATIONS
127	Cost-effectiveness of the Conventional Papanicolaou Test With a New Adjunct to Cytological Screening for Squamous Cell Carcinoma of the Uterine Cervix and Its Precursors. Archives of Family Medicine, 2000, 9, 713-721.	1.5	13
128	Leukocytes in the Cervix. Obstetrics and Gynecology, 1998, 91, 987-992.	1.2	7
129	Colposcopy Quality Control. Journal of Lower Genital Tract Disease, 1998, 2, 195-203.	0.9	29
130	Multi-wavelength Digital Colposcopy to Aid Early Detection of Cervical Cancer. , 1998, , .		1
131	The Efficacy of Topical Benzocaine Gel in Providing Anesthesia Prior to Cervical Biopsy and Endocervical Curettage. Journal of Lower Genital Tract Disease, 1997, 1, 221-227.	0.9	2
132	Is LEEP the Cesarean Delivery of Cervical Intraepithelial Neoplasia?. Journal of Lower Genital Tract Disease, 1997, 1, 257-259.	0.9	0
133	What is a cost-effectiveness analysis?. Archives of Family Medicine, 1997, 6, 527-528.	1.5	0
134	Topical benzocaine: Does it alleviate pain? Who knows?. American Journal of Obstetrics and Gynecology, 1996, 174, 1077.	0.7	0
135	Elastin fibers resembling Sporothrix schenckii in the skin of a patient with acquired immunodeficiency syndrome. Archives of Pathology and Laboratory Medicine, 1995, 119, 744-8.	1.2	1
136	Colposcopy for family physicians. Archives of Family Medicine, 1994, 3, 400-401.	1.5	0
137	Anesthetic blocks for loop electrosurgical excision procedure. Journal of Family Practice, 1994, 39, 249-56.	0.2	6
138	Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status. Journal of Clinical Oncology, 0, , .	0.8	4
139	US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study. ELife, 0, 11, .	2.8	3